Bovine Factor V/Va: Preparation & Functional Assay Protocol

Bovine Factor V/Va is a high-molecular-weight plasma glycoprotein cofactor that serves as an essential component of the prothrombinase complex, dramatically accelerating thrombin generation in coagulation cascade research.

Product SKU

B1526738

Source / Reference Standard

Enzyme Research Laboratories (ERL) #BFV/Va

Species Origin

Bovine (Bos taurus) plasma

Functional Role

Non-enzymatic cofactor of the prothrombinase complex (Factor Xa + Factor Va + phospholipid + Ca²⁺)

Activation

Factor V is activated to Factor Va by limited proteolysis with thrombin or Factor Xa

Storage Recommendation

Store at -80 °C; avoid repeated freeze-thaw cycles

Background & Biological Function

Bovine Factor V is a large, single-chain plasma glycoprotein (Mr ~330 kDa) synthesized in hepatocytes and megakaryocytes. It circulates in plasma as an inactive procofactor and is converted to the active two-chain cofactor Factor Va by limited proteolysis mediated by thrombin or Factor Xa. Factor Va is composed of a heavy chain (~105 kDa) and a light chain (~74 kDa) held together by a Ca²⁺-dependent, non-covalent interaction.

Factor Va functions as the critical non-enzymatic cofactor within the prothrombinase complex (Factor Xa · Factor Va · phospholipid membrane · Ca²⁺). Assembly of this complex increases the catalytic efficiency of Factor Xa-mediated prothrombin activation by several orders of magnitude compared with Factor Xa alone, making Factor V/Va indispensable for physiologically relevant rates of thrombin generation.

Bovine Factor V/Va sourced from Enzyme Research Laboratories (ERL, #BFV/Va) is widely used in academic and industrial coagulation research as a well-characterized reference reagent, offering the advantage of high batch-to-batch consistency for kinetic studies of the prothrombinase complex.

Materials & Reagents

Required reagents and consumables:

• Bovine Factor V/Va (Aladdin SKU B1526738, ERL #BFV/Va)
• Reconstitution buffer: 50 mM HEPES or Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM CaCl₂
• Bovine Factor Xa (for prothrombinase assembly)
• Bovine prothrombin (substrate)
• Phospholipid vesicles (e.g., 75:25 PC:PS or PCPS; 100 µM final)
• Calcium chloride solution (1 M stock)
• Chromogenic or fluorogenic thrombin substrate (e.g., S-2238 or Tos-Gly-Pro-Arg-AMC)
• Bovine serum albumin (BSA, 0.1% w/v, for protein stabilization in dilution buffers)
• Microplate reader (405 nm or fluorescence compatible)
• Low-protein-binding microcentrifuge tubes
• Ice and wet ice bucket

Note: All reagent concentrations and buffer compositions listed are representative starting points from standard coagulation biochemistry practice. Verify optimal conditions empirically for your specific experimental system.

Step-by-Step Protocol

Step 1: Reconstitution of Bovine Factor V/Va

1. Thaw the lyophilized or frozen Factor V/Va vial on ice (do not use a 37 °C water bath to avoid denaturation).
2. Briefly centrifuge the vial (1,000 × g, 10 s) to collect contents at the bottom.
3. Reconstitute with the manufacturer-specified volume of cold reconstitution buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 5 mM CaCl₂). Refer to the product Certificate of Analysis (CoA) for the exact target concentration.
4. Gently invert or swirl to dissolve — do NOT vortex.
5. Allow 5–10 minutes on ice for complete dissolution.
6. Aliquot into single-use low-protein-binding tubes and snap-freeze unused portions in liquid nitrogen; store at -80 °C.

Step 2: Activation of Factor V to Factor Va (if starting from Factor V)

1. Prepare thrombin solution (e.g., 1 NIH U/mL) in reconstitution buffer.
2. Mix Factor V with thrombin at a ratio of approximately 1:50 (w/w) in the presence of 5 mM CaCl₂.
3. Incubate at 37 °C for 10 minutes.
4. Inactivate thrombin by adding hirudin (2-fold molar excess) or by using a thrombin-specific inhibitor, to prevent further proteolysis of Factor Va.
5. Confirm activation by SDS-PAGE: Factor V heavy chain (~330 kDa) should be cleaved to yield the Va heavy chain (~105 kDa) and Va light chain (~74 kDa).

Step 3: Prothrombinase Complex Assembly

1. In a microcentrifuge tube, pre-incubate phospholipid vesicles (PCPS, 100 µM final) with CaCl₂ (5 mM final) in assay buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 0.1% BSA) for 5 minutes at 37 °C.
2. Add Factor Va to the phospholipid-Ca²⁺ mixture and incubate for 2 minutes at 37 °C.
3. Add Factor Xa to initiate complex formation; incubate 2 minutes at 37 °C.
4. Initiate the reaction by adding prothrombin (substrate) to the desired final concentration (e.g., 1–2 µM). Use concentrations spanning the Km for kinetic analyses.

Step 4: Thrombin Generation Measurement

1. At defined time points, remove aliquots and quench into EDTA-containing stop solution (50 mM EDTA, final) or dilute into chromogenic substrate solution.
2. For chromogenic assays, add S-2238 (0.2 mM final) and measure absorbance at 405 nm.
3. For fluorogenic assays, add Tos-Gly-Pro-Arg-AMC and read fluorescence (Ex 380 nm / Em 450 nm).
4. Calculate thrombin concentration from a standard curve generated with purified thrombin of known activity.

Troubleshooting & Critical Tips

Problem	Likely Cause	Recommended Action
Low or absent thrombin generation signal	Incomplete Factor V activation; protein aggregation; loss of activity due to freeze-thaw	Verify activation by SDS-PAGE; use fresh single-use aliquots; confirm phospholipid vesicle quality
High background absorbance/fluorescence	Substrate auto-hydrolysis; contaminating proteases	Include no-enzyme controls; use freshly prepared substrate solutions; filter buffers (0.22 µm)
Poor reproducibility between replicates	Pipetting error with viscous protein solutions; incomplete mixing	Pre-wet pipette tips with protein solution; mix gently by pipetting before use; equilibrate all reagents to 37 °C
Rapid loss of Factor Va activity	Spontaneous dissociation of heavy and light chains; proteolytic degradation	Maintain Ca²⁺ (≥5 mM) at all steps; keep samples on ice when not in use; minimize handling time

Tip: Always include a positive control (e.g., a previously characterized Factor Va lot with known specific activity) to validate each experiment.

Expected Results & Data Interpretation

Under optimally assembled prothrombinase complex conditions, thrombin generation should exhibit a characteristic burst-phase kinetics profile when measured by continuous fluorogenic substrate cleavage. Key quality indicators include:

• Lag phase duration: Short lag phase (seconds to low minutes) under saturating Factor Va and Factor Xa concentrations on phospholipid surfaces, consistent with rapid complex assembly.
• Linearity of thrombin generation: The initial rate (V₀) should be linear with respect to prothrombin concentration at sub-Km substrate levels, confirming Michaelis-Menten behavior.
• Factor Va concentration dependence: Thrombin generation rate should increase with increasing Factor Va up to saturating concentrations, reaching a plateau that reflects maximal cofactor-stimulated Factor Xa activity.
• SDS-PAGE verification: Active Factor Va preparation should display two distinct bands corresponding to the heavy chain (~105 kDa) and light chain (~74 kDa) under non-reducing SDS-PAGE conditions.

If the plateau rate is significantly lower than expected from literature or previous lots, consider the possibility of partial inactivation by Activated Protein C (APC) contamination or spontaneous chain dissociation during storage.

Frequently asked questions

What is the difference between Bovine Factor V and Bovine Factor Va?

Bovine Factor V is the intact, single-chain procofactor form that circulates in plasma and has minimal cofactor activity. Bovine Factor Va is the proteolytically activated, two-chain form generated by thrombin or Factor Xa cleavage; it possesses full cofactor activity within the prothrombinase complex. The ERL #BFV/Va product may contain a mixture or predominantly the activated form — consult the product CoA for the specific activation state.

Why is calcium chloride essential in all handling buffers for Factor Va?

Calcium ions (Ca²⁺) are required to maintain the non-covalent interaction between the Factor Va heavy chain and light chain. In the absence of Ca²⁺, the two-chain structure dissociates, resulting in rapid and irreversible loss of cofactor activity. Maintaining at least 5 mM CaCl₂ in all storage and assay buffers is therefore critical to preserve functional integrity.

Can Bovine Factor V/Va be used as a substitute for human Factor Va in clinical-grade assays?

Bovine Factor V/Va is intended for research use only (RUO) and is not validated for clinical diagnostic or therapeutic applications. While bovine and human Factor V share significant structural and functional homology, species differences in specific activity, glycosylation, and regulatory interactions (e.g., sensitivity to Activated Protein C) mean that results obtained with bovine reagents should not be directly extrapolated to human clinical contexts without appropriate validation.

How should I determine the optimal concentration of Factor Va for my prothrombinase assay?

Perform a Factor Va titration experiment: keep Factor Xa, phospholipid, Ca²⁺, and prothrombin concentrations constant while varying Factor Va over a range spanning at least two orders of magnitude (e.g., 0.1 nM to 100 nM). Plot initial thrombin generation rate versus Factor Va concentration to identify the saturating (Vmax) plateau. Use a concentration within the saturating range for routine assays to ensure maximal complex occupancy.

References

1. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem. 1988;57:915-956.
2. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem. 1979;254(21):10952-10962.
3. Enzyme Research Laboratories. Bovine Factor V/Va product information sheet, ERL #BFV/Va. South Bend, IN: Enzyme Research Laboratories.
4. Krishnaswamy S, Mann KG, Nesheim ME. The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction. J Biol Chem. 1986;261(19):8977-8984.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.